<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416622</url>
  </required_header>
  <id_info>
    <org_study_id>AGTC-RS1-001</org_study_id>
    <nct_id>NCT02416622</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)</brief_title>
  <official_title>A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Genetic Technologies Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Genetic Technologies Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of a recombinant adeno-associated virus
      vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis.
      Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose
      escalation format.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a non-randomized, open label, Phase 1/2 dose escalation study.

      Up to 27 participants will be enrolled. Each participant will receive the study agent by
      intravitreal injection in one eye on a single occasion. Enrollment will begin with the lowest
      dose and will proceed to higher doses only after review of safety data by a Data and Safety
      Monitoring Committee (DSMC). Participants in the dose escalation phase will be ≥ 18 years of
      age. After the maximum tolerated dose is identified individuals ≥ 6 years of age will be
      enrolled.

      Safety will be measured by the number and proportion of participants experiencing adverse
      events and immune response to RS1. Efficacy will be measured by evaluation of changes in
      visual function and schisis cavity size.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing adverse events</measure>
    <time_frame>From Day 0 to Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in visual acuity</measure>
    <time_frame>From Day 0 to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in schisis cavity size on optical coherence tomography (OCT)</measure>
    <time_frame>From Day 0 to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in b-wave amplitude in electroretinogram (ERG) responses</measure>
    <time_frame>From Day 0 to Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>X-linked Retinoschisis</condition>
  <arm_group>
    <arm_group_label>Groups 1A and 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Groups 2 and 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 6 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rAAV2tYF-CB-hRS1</intervention_name>
    <description>adeno-associated virus vector expressing retinoschisin</description>
    <arm_group_label>Groups 1A and 1B</arm_group_label>
    <arm_group_label>Groups 2 and 2A</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          1. Retinal disease consistent with a diagnosis of XLRS and documented mutations in the
             RS1 gene

          2. Male individual at least 18 years of age (dose escalation phase) or at least 6 years
             of age (maximum tolerated dose phase),

          3. Able to perform tests of visual and retinal function,

          4. Visual acuity specified for each group

          5. Not treated with CAIs currently or within 3 months prior to study enrollment,

          6. Have acceptable laboratory parameters.

        Exclusion Criteria include:

          1. Prior receipt of any AAV gene therapy product,

          2. Pre-existing eye conditions that would preclude the planned intravitreal injection or
             interfere with interpretation of study endpoints or complications of vector
             administration.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Feinsod, MD</last_name>
    <role>Study Director</role>
    <affiliation>Applied Genetics Technologies Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Dolgin, PharmD</last_name>
    <email>advocacy@agtc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco, Dept. of Ophthalmology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami - Miller School of Medicine Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Wilmer Eye Institute, Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center, Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute, Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, Alkek Eye Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://agtc.com</url>
    <description>AGTC website</description>
  </link>
  <reference>
    <citation>Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res. 2012 May;31(3):195-212. doi: 10.1016/j.preteyeres.2011.12.002. Epub 2012 Jan 3. Review.</citation>
    <PMID>22245536</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2015</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XLRS</keyword>
  <keyword>maculoschisis</keyword>
  <keyword>retinal degeneration</keyword>
  <keyword>RS1</keyword>
  <keyword>adeno-associated virus</keyword>
  <keyword>gene therapy</keyword>
  <keyword>AAV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoschisis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

